Flag of the European Union EU Clinical Trials Register Help

Clinical trials for bladder cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: bladder cancer. Displaying page 3 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004876-16 Sponsor Protocol Number: SURE-02 Start Date*: 2021-11-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-ba...
    Medical condition: muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003625-17 Sponsor Protocol Number: CA209-275 Start Date*: 2015-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...
    Medical condition: metastatic or unresectable urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046723 Urothelial carcinoma ureter LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018246-38 Sponsor Protocol Number: Jun_11_2009_Updated_Nov_2009 Start Date*: 2010-12-23
    Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder
    Medical condition: patients with muscle invasive transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005017 Bladder carcinoma stage 0, with cancer in situ LLT
    12.1 10005019 Bladder carcinoma stage I, with cancer in situ LLT
    12.1 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005452-38 Sponsor Protocol Number: D910PC00001 Start Date*: 2021-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With En...
    Medical condition: Cisplatin ineligible patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005095-18 Sponsor Protocol Number: ICR-CTSU/2013/10041 Start Date*: 2014-09-19
    Sponsor Name:The Institute of Cancer Research
    Full Title: A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
    Medical condition: Low risk non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-002408-26 Sponsor Protocol Number: 42756493BLC2001 Start Date*: 2015-04-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metast...
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) DE (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) RO (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004671-19 Sponsor Protocol Number: PDX 011 Start Date*: 2008-06-06
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Medical condition: Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007294 Carcinoma bladder recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014264-19 Sponsor Protocol Number: 0908038 Start Date*: 2010-01-14
    Sponsor Name:Clinique Mutualiste Chirurgicale
    Full Title: Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) ...
    Medical condition: bladder infiltrative urothelium carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001826-28 Sponsor Protocol Number: BL-2007-02 Start Date*: 2007-11-28
    Sponsor Name:Queen Mary University London
    Full Title: A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after firrst-line chemotherapy in patients with HER1 and/or HER2 over expressing locally advanced or metastati...
    Medical condition: The medical condition being investigated in this trial is locally advanced or metastatic urological cancer. The tumour must overexpress HER1 and/or HER2 gene.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019181-91 Sponsor Protocol Number: EAURF2008-01 Start Date*: 2013-05-24
    Sponsor Name:EAU Foundation for Urological Research
    Full Title: Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations wi...
    Medical condition: Non muscle invasive bladder cancer after transurethral resection of the Bladder Tumor (TURT).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002765-22 Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-2/NEODURVARIB Start Date*: 2018-09-04
    Sponsor Name:Spanish Oncology Genitourinary Group - SOGUG
    Full Title: Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer
    Medical condition: Resectable urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003813-92 Sponsor Protocol Number: EPT02/2016 Start Date*: 2017-01-25
    Sponsor Name:IBSA FARMACEUTICI ITALIA SRL
    Full Title: Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low r...
    Medical condition: Low risk not muscle-infiltrating bladder neoplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002676-40 Sponsor Protocol Number: CA045-009 Start Date*: 2019-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Can...
    Medical condition: Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) GR (Completed) ES (Ongoing) CZ (Completed) PL (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011049-15 Sponsor Protocol Number: IB 2009–08 Start Date*: 2009-06-29
    Sponsor Name:Institut Bergonié - Département d’Oncologie Médicale
    Full Title: Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique.
    Medical condition: Cancer de la vessie récidivant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028983 Neoplasm bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001823-38 Sponsor Protocol Number: AB65/18 Start Date*: 2018-11-26
    Sponsor Name:Technische Universität München, Fakultät für Medizin vertreten durch den Dekan
    Full Title: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urot...
    Medical condition: Locally advanced urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007591-42 Sponsor Protocol Number: SPON416-07(WCTU011) Start Date*: 2009-01-14
    Sponsor Name:Cardiff University
    Full Title: A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium.
    Medical condition: Advanced transitional cell carcinoma of the urothelium.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    9.1 10038517 Renal pelvis cancer NOS LLT
    9.1 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002100-13 Sponsor Protocol Number: ESR-16-12611 Start Date*: 2018-10-11
    Sponsor Name:Hellenic GenitoUrinaty Cancer Group (HGUCG)
    Full Title: Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies.
    Medical condition: Non-muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022653-41 Sponsor Protocol Number: INT52/10 Start Date*: 2010-11-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.
    Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005084 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012714-49 Sponsor Protocol Number: CHUBX 2009/04 Start Date*: 2009-11-24
    Sponsor Name:CHU de Bordeaux
    Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy
    Medical condition: Bladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005015 Bladder carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004844-27 Sponsor Protocol Number: SURE-01 Start Date*: 2021-06-01
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-01_An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cispl...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007293 Carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 09:08:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA